Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.

Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I? and pharmaceutically acceptable esters or salts thereof.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A railway vehicle with an aerodynamic lift control device is disclosed. An equipment compartment is formed between a vehicle body bottom plate at the bottom of a vehicle body and a passenger room floor, and the aerodynamic lift control device is provided in the equipment compartment; the aerodynamic lift control device comprises an aerodynamic lift regulation fan and aerodynamic lift air ducts, and an aerodynamic lift regulation air port located within the aerodynamic lift control range is formed in the vehicle body bottom plate; one end of each aerodynamic lift regulating air duct communicates with the aerodynamic lift regulation air port, and the other end communicates with the aerodynamic lift regulating fan; and the aerodynamic lift regulation fan changes the pressure distribution form of the bottom of the train by blowing positive pressure airflow or sucking negative pressure airflow.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A positioning method for a user equipment (UE) and an associated electronic device, the method including after a UE initiates a positioning request, receiving, by the UE, first supplementary information sent by a Location Management Function (LMF), where the first supplementary information comprises Synchronization Signal Block beam polling information of a designated cell reported to the LMF by a Next Generation Radio Access Network, measuring, by the UE, the designated cell to acquire first measurement information, and determining, by the UE, a position of the UE according to the first measurement information and the first supplementary information.

Abstract: Provided are a networking signal sending method and device for a positioning network. The method includes: determining a networking mode of the positioning network according to an application scene, wherein the networking mode includes independent networking of the positioning network and joint networking of the positioning network and a communication network; and configuring a positioning base station of the positioning network, or the positioning base station and a communication base station according to the networking mode, wherein the positioning base station is used for sending a positioning signal or the positioning signal and a synchronization signal, and the communication base station is used for sending the synchronization signal.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: Disclosed are a cooperative positioning method and apparatus, a device, and a non-transitory computer-readable storage medium. The method may include: determining an initial positioning estimated value of each of a plurality of objects to be measured by a simulated annealing algorithm and a first preset positioning algorithm; screening at least two distance measurement values based on a preset error threshold to obtain a target distance measurement value, where the at least two distance measurement values are measurement values obtained by measuring a distance between each object to be measured and each of a plurality of target base stations for at least two times; and determining a position of each object to be measured according to a multi-target-source Taylor series algorithm, each target distance measurement value and each initial positioning estimated value.

Abstract: A railway vehicle with an aerodynamic lift control device is disclosed. An equipment compartment is formed between a vehicle body bottom plate at the bottom of a vehicle body and a passenger room floor, and the aerodynamic lift control device is provided in the equipment compartment the aerodynamic lift control device comprises an aerodynamic lift regulation fan and aerodynamic lift air ducts, and an aerodynamic lift regulation air port located within the aerodynamic lift control range is formed in the vehicle body bottom plate; one end of each aerodynamic lift regulating air duct communicates with the aerodynamic lift regulation air port, and the other end communicates with the aerodynamic lift regulating fan; and the aerodynamic lift regulation fan changes the pressure distribution form of the bottom of the train by blowing positive pressure airflow or sucking negative pressure airflow.

Abstract: A method includes receiving a request from a vehicle to perform a computing task, selecting a machine learning model from among a plurality of machine learning models based at least in part on the request, and predicting an amount of computing resources needed to perform the computing task using the selected machine learning model.

Abstract: Disclosed are a method and an apparatus for determining time of arrival, a signal receiving device, and a non-transitory computer readable storage medium. The method for determining time of arrival includes: generating time of arrival correction information according to front edge information of theoretical autocorrelation waveforms of positioning signals having different fading values; calculating a front edge slope corresponding to a front edge reference point of a correlation waveform of an actually received signal; and determining target correction information from the time of arrival correction information according to the front edge slope, and determining the time of arrival of the actually received signal based on the target correction information.

Abstract: There are provided bivalent compounds and conjugates thereof, the conjugates comprising a bivalent compound, a targeting moiety, and a bioactive agent, as well as pharmaceutical compositions and methods of use of the conjugate for the treatment, inhibition, or prevention of diseases and disorders which are therapeutic targets of the bioactive agent.

Abstract: A method and device for determining a time of arrival (TOA), a terminal device, and a non-transitory computer-readable storage medium are disclosed. The method may include: determining a detection start time on a correlation waveform based on a leading edge detection threshold; determining a noise threshold on the correlation waveform, and determining a quasi-TOA according to the detection start time; and determining the TOA according to data information in a target area of the correlation waveform and the noise threshold, where the target area is determined based on the quasi-TOA and a detection length.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: The disclosure includes embodiments including a vehicular edge server switching mechanism based on historical data and digital twin simulations. A method includes causing a sensor set of a connected vehicle to determine a current driving context of the connected vehicle. A method includes comparing the current driving context to a set of digital twin data and a set of historical data to determine a predicted latency for using offboard computing resources of an edge server. The method includes determining that the predicted latency for using the offboard computing resources satisfies a threshold for the predicted latency. The method includes executing a switching decision that includes deciding to use the offboard computing resources of the edge server based on the comparing of the current driving context to the set of digital twin data and the set of historical data and the determining that the threshold for the predicted latency is satisfied.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.